GenSight Biologics obtains a €7m non-dilutive loan and renegotiates the bond agreement with Kreos Capital extending runway to mid-2021

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

BIO 2020, San Diego (CA), US – Digital

GenSight Biologics will hold its General Meeting on April 29, 2020 behind closed doors

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update

Annual General Meeting on April 29, 2020 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2019 Universal Registration Document

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020